P28-1 Improving survival in EGFR mutation-positive non-small cell lung cancer: Tokushukai REAl world Data project (TREAD 01)

Kiyoaki Uryu,Imamura Yosinori,Shimoyama Rai,Mase Takahiro,Fujimura Yoshiaki,Hayashi Maki,Ohtaki Megu,Otani Keiko,Shinozaki Nobuaki,Minami Hironobu

Annals of Oncology（2022）

引用 0|浏览0

暂无评分

摘要

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become established treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC). The aim of this study was to investigate prognostic factors and temporal trends in treatment pattern for overall survival (OS) in a real-world setting.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要